BriaCell Quadruples PFS to 9.1 Months in Top Responder Metastatic Breast Cancer Patient

BriaCell Therapeutics Corp.

PFS extended to 9.1 months in top responder patient, quadruple historical controls (1.7-2.3 months).
Patient had failed 8 prior regimens including ADC therapy; continues on BriaCell treatment.
Brain lesion undetectable, orbital lesion shrinking; tumor markers markedly decreased from pre-treatment.
Phase 2 study of Bria-IMT regimen plus immune checkpoint inhibitor in metastatic breast cancer.
Patient remains alive; company plans to replicate results in ongoing Phase 3 study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.